A Kunjin Replicon Virus-like Particle Vaccine Provides Protection Against Ebola Virus Infection in Nonhuman Primates
A Kunjin Replicon Virus-like Particle Vaccine Provides Protection Against Ebola Virus Infection in Nonhuman Primates
复制标题
DOI：
10.1093/infdis/jiv019
复制
发表时间：
2015-10-01
影响因子：
6.4
通讯作者：
Khromykh, Alexander A.
中科院分区：
文献类型：
--
作者：
Pyankov, Oleg V.;Bodnev, Sergey A.;Khromykh, Alexander A.
西非目前史无前例的埃博拉病毒(EBOV)疫情表明，迫切需要一种疫苗。在这里，我们描述了基于昆津复制子病毒样颗粒(Kun VLP)编码带有D637L突变的EBOV糖蛋白(GP/D637L)的EBOV候选疫苗在非人类灵长类动物中的评估。4只非洲绿猴每只皮下注射10(9)Kun VLP，间隔4周，3周后肌肉注射600个Zaire EBOV空斑单位。3只动物完全抵抗EBOV攻击，1只接种疫苗的动物和对照动物死于感染。我们认为编码gP/D637L的Kun VLP代表了一种可行的EBOV疫苗候选方案。
The current unprecedented outbreak of Ebola virus (EBOV) disease in West Africa has demonstrated the urgent need for a vaccine. Here, we describe the evaluation of an EBOV vaccine candidate based on Kunjin replicon virus-like particles (KUN VLPs) encoding EBOV glycoprotein with a D637L mutation (GP/D637L) in nonhuman primates. Four African green monkeys (Cercopithecus aethiops) were injected subcutaneously with a dose of 10(9) KUN VLPs per animal twice with an interval of 4 weeks, and animals were challenged 3 weeks later intramuscularly with 600 plaque-forming units of Zaire EBOV. Three animals were completely protected against EBOV challenge, while one vaccinated animal and the control animal died from infection. We suggest that KUN VLPs encoding GP/D637L represent a viable EBOV vaccine candidate.